Aquinnah Pharmaceuticals, founded by Dr. Benjamin Wolozin, M.D., Ph.D., focuses on developing drugs that target neurodegenerative stress granules to combat diseases like amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The company's core mission is to advance groundbreaking therapies that address the underlying mechanisms of neurodegenerative diseases, aiming to significantly improve patient outcomes. Their innovative approach centers on modulating stress granules, which are believed to play a crucial role in the pathology of these conditions.

Notable figures affiliated with Aquinnah include co-founder and Chief Scientific Officer Dr. Benjamin Wolozin, who is recognized for his pioneering work in linking stress granules to neurodegenerative diseases. The company has achieved significant milestones, including preclinical research demonstrating a novel therapeutic's potential to reduce brain tau pathology by approximately 70% in Alzheimer's disease models. Aquinnah's impact lies in its potential to revolutionize treatment paradigms for debilitating neurodegenerative disorders, offering new hope for patients and advancing the field of neurological research.